In this context, daratumumab may also restore the osteoclast-induced immunosuppressive T-cell phenotype in the myeloma bone marrow milieu by reducing the levels of galectin-9 and a proliferation-induced ligand (APRIL) secreted by osteoclasts [23]. Here, LGALS9 is linked to plasma cell myeloma.